Oncogenic drivers dictate immune control of acute myeloid leukemia

Oncogenic drivers dictate immune control of acute myeloid leukemia

Blog Article

Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous, aggressive hematological malignancy induced by distinct oncogenic driver mutations.The effect of specific AML oncogenes on immune activation or suppression is unclear.Here, we examine immune responses in genetically distinct VITAMIN C CRYSTALS 1000MG models of AML and demonstrate that specific AML oncogenes dictate immunogenicity, the quality of immune response and immune escape through immunoediting.Specifically, expression of NrasG12D alone is sufficient to drive a Heart Puzzle Keychain Gift Box potent anti-leukemia response through increased MHC Class II expression that can be overcome with increased expression of Myc.

These data have important implications for the design and implementation of personalized immunotherapies for patients with AML.